Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine
CD38, A Target for Immunotherapeutic Approaches in Cancer
Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence - Kitadate - 2021 - Cancer Science - Wiley Online Library
Blood and Hematology - CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
International Clinical Cytometry Society
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes | SpringerLink
Immunophenotyping | plasma cells | human multiple myeloma bone marrow | Protocol | Italia
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
Frontiers | Daratumumab for the Treatment of Multiple Myeloma
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article
